Effects of SGLT2 Inhibitors on Circulating Cyclophilin A Levels in Patients with Type 2 Diabetes
Beyond the improvement of metabolic parameters, SGLT2 treatment reduced CypA levels in patients with DM regardless of drug subgroups. These drugs may further prevent the presence of cardiovascular diseases.
Authors
- Furkan Kılıç (ORCID: https://orcid.org/0000-0002-2867-9831)
- Rabia Eker Akıllı (ORCID: https://orcid.org/0000-0003-4922-6556)
- Oğuz Akkuş (ORCID: https://orcid.org/0000-0001-7988-7027)
- Fulya Odabaş (ORCID: https://orcid.org/0000-0001-6110-6106)
- Gamze Akkuş (ORCID: https://orcid.org/0000-0002-0976-159X)
- Abdulkadir İltaş (ORCID: https://orcid.org/0000-0002-2536-7541)
- Gülçin Dağlıoğlu (ORCID: https://orcid.org/0000-0003-2454-3723)
Institutions
- Mustafa Kemal University (TR)
- Cukurova University (TR)
Publication Details
- Journal
- Current Medicinal Chemistry
- Published
- 2025-10-29
- DOI
- https://doi.org/10.2174/0109298673406989251010070419
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00